Generation Bio Co.
Generation Bio Co. is a U.S.-based biotechnology company developing redosable therapeutics designed to reprogram T cells in vivo for T cell-driven autoimmune diseases. The company is still in the research and development stage, with no approved products and current revenue coming primarily from its collaboration with Moderna.
Tilikausi 2024 · muutos edellisvuodesta
Kehitys 2019–2024
Liiketoiminta
Osuus liikevaihdostaCore technology for reprogramming T cells in vivo to address autoimmune disease biology.
Revenue recognized from research collaboration and related services, primarily with Moderna.
Internal drug discovery and preclinical programs advancing product candidates toward clinical testing.
Development of manufacturing capabilities and supply chain readiness for future clinical or commercial use.
Asiakkaat
Generation Bio does not sell approved products today; its current counterparties are collaboration partners, most notably Moderna, that fund or support research activities. If its programs succeed, future customers would be healthcare providers, patients, and payers in autoimmune disease markets, but that remains several years away and is not yet commercialized.
Biopharma partners such as Moderna that fund research, share development risk, and may license or co-develop platform assets.
Patients with T cell-driven autoimmune diseases who would use any approved redosable therapeutic if clinical development succeeds.
Specialists and treatment centers that would prescribe and administer future therapies in autoimmune indications.
Insurers and health systems that would determine reimbursement and access for any commercial product.
Strategia
The company is focused on advancing its T-cell reprogramming platform, maintaining core research capabilities, and preserving intellectual property while it evaluates strategic alternatives. Management is also trying to extend cash runway through restructuring, collaborations, and potential financing or transaction options.
Progressing the platform is necessary to create clinical assets and future partnering value.
IP is central to platform defensibility and future licensing or acquisition value.
The company needs to extend runway while it evaluates strategic options and uncertain development timelines.
A transaction could monetize the platform or provide a path to value creation if standalone development is not viable.
Maantiede
Generation Bio is headquartered in the United States and conducts its research and corporate operations there. The company has not disclosed meaningful country revenue concentration because it has no product sales; near-term revenue is tied to collaboration activity rather than geography of end customers.
Riskit
Generation Bio faces the classic risks of an early-stage biotech company: clinical, regulatory, financing, and execution uncertainty. The current strategic review and restructuring add additional uncertainty around whether the company can complete a value-maximizing transaction, preserve talent, and avoid further dilution or liquidation.
- Failure to develop and commercialize product candidatesVaikutus: Kriittinen
The company has no approved products, so value depends on successful preclinical and clinical progress.
Kohdistuu: Entire business model
- Insufficient funding and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Operations require substantial additional capital and financing may come through dilutive equity or unfavorable terms.
Kohdistuu: Cash runway and development continuity
- Strategic alternatives may not closeVaikutus: KorkeaTodennäköisyys: Korkea
The company has announced a review process, but there is no assurance of a transaction or attractive terms.
Kohdistuu: Shareholder value and going-forward strategy
- Workforce reduction and restructuring execution riskVaikutus: KorkeaTodennäköisyys: Korkea
A roughly 90% workforce reduction can impair research continuity, institutional knowledge, and morale.
Kohdistuu: R&D productivity and retention
- Dependence on Moderna collaborationVaikutus: Keskitaso
Near-term revenue is largely collaboration-based, so changes in the partnership would affect funding and operations.
Kohdistuu: Revenue and liquidity
Kirjanpito
Harkinnanvaraiset erätRevenue from Moderna depends on research services, plan revisions, and reimbursable activity, creating quarter-to-quarter volatility.
Vaikutus: Affects reported revenue and operating loss
The 2025 workforce reduction is expected to generate severance, retention, and benefit costs.
Vaikutus: Affects operating expenses and cash usage
Prior lease-related actions produced a large loss on lease termination, showing sensitivity to facility decisions.
Vaikutus: Can create non-recurring expense spikes
Equity awards are a meaningful component of personnel expense in a development-stage biotech.
Vaikutus: Affects R&D and G&A expense
Management’s runway estimate depends on assumptions about spending, collaboration receipts, and financing access.
Vaikutus: Affects investor assessment of solvency and dilution risk
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Regen BioPharma Inc
RGBPP · Pharmaceutical Preparations
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc.
Green Planet Bio Engineering Co. Ltd.
GPLB · Biological Products, (No Diagnostic Substances)
Green Planet Bio Engineering Co.
Korro Bio, Inc.
KRRO · Pharmaceutical Preparations
BioRestorative Therapies, Inc.
BRTX · Services-Misc Health & Allied Services, NEC
Päivitetty: 24.9.2026